Funded Startups in South San Francisco
Across the 50 most recent rounds listed for South San Francisco, the largest disclosed amount is IDEAYA Biosciences at $345M (2026-06-08).
Across the 50 most recent rounds listed for South San Francisco, the largest disclosed amount is IDEAYA Biosciences at $345M (2026-06-08). That single round dwarfs most other disclosed figures in the table; for example, several major biotech rounds sit at $300K–$257M (e.g., Atara Biotherapeutics at $550K on 2026-05-01, Cellares at $257M on 2026-01-28, and Vera Therapeutics at $261M on 2025-12-09). The smallest disclosed amount is $1M, appearing for Senti Biosciences on 2025-05-22 and also for Titan Pharmaceuticals on 2025-04-11.
Rounds concentrate in a narrow recent window: the most recent date is 2026-06-22 (Nura Bio, $74M), while the oldest date shown is 2024-04-02 (Sutro Biopharma; amount $75M). Sector-wise, Biotechnology appears in 3+ entries (including Nura Bio, IDEAYA Biosciences, NewLimit, and many others), and “Series Unknown” is frequent (12 rows) alongside a smaller “undisclosed” amount pattern (2 rows: Cartography Biosciences and Atlas Data Storage).
Most recent rounds
50 of 9040 more funded startups
This page shows the 50 most recent rounds (back to Apr 2024). The full 90-company history for this listing is available on a paid plan.
Unlock all 90 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What does the largest disclosed round look like relative to other disclosed amounts in this South San Francisco set?
IDEAYA Biosciences’ $345M (2026-06-08) is the largest disclosed amount and sits far above many others, including $325M (ArsenalBio, 2024-09-04) and $300M (Rapt Therapeutics, 2025-10-21) that still fall well below $345M.
Do the deals cluster tightly by time, or are they spread across the full date range shown?
The list’s timeline runs from 2024-04-02 (Sutro Biopharma, $75M) to 2026-06-22 (Nura Bio, $74M). Many of the biggest entries appear in June 2026 (e.g., NewLimit $435M on 2026-06-02; IDEAYA Biosciences $345M on 2026-06-08), indicating a recent concentration near the right edge.
Are there notable outliers that differ in scale or disclosure type?
Yes. Atara Biotherapeutics’ disclosed $550K (2026-05-01) is a sharp low outlier compared with multiple nine-figure-near rounds like NewLimit’s $435M (2026-06-02). Disclosure outliers also show up as “undisclosed” amounts in Cartography Biosciences (2026-05-06) and Atlas Data Storage (2026-03-05), which can’t be compared to the disclosed-size distribution.
How dominant is stage specificity here—does “Series Unknown” appear often enough to affect analysis?
“Series Unknown” is common in this table (12 of 50 rows), including Genesis Molecular AI ($40M on 2026-05-20) and Structure Therapeutics ($748M on 2025-12-09). “Undisclosed” amounts are rarer (2 rows: Cartography Biosciences on 2026-05-06 and Atlas Data Storage on 2026-03-05), so most comparisons across size can still use disclosed figures.
Which company/sector pattern appears repeatedly enough to treat as a structural cluster?
Biotechnology appears in 3+ entries and is the most consistently represented sector across both the newest and older rows—for example Nura Bio ($74M, 2026-06-22), Allogene Therapeutics ($200M, 2026-04-14), and Cytokinetics ($550M, 2024-05-22). Health Care also appears multiple times (e.g., Star Therapeutics $125M on 2025-09-29; InterVene $13M on 2024-10-07), but Biotechnology is the clearest repeated theme.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.